The first patient has been dosed in a phase 2 clinical trial investigating EYP-1901 for the treatment of diabetic macular edema, according to a press release from EyePoint Pharmaceuticals.
The company expects to enroll approximately 25 patients in the randomized, controlled, single-masked VERONA trial. Patients will receive one of two intravitreal doses of EYP-1901, an investigational sustained delivery therapy containing vorolanib, or aflibercept control.
The primary efficacy endpoint is the time to first supplemental aflibercept injection up to 24 weeks. Secondary endpoints will assess